The Signal
Three separate conviction traders are stacking identical bets across drone, robotics, and autonomous systems infrastructure. $BB (QNX OS moat in 275M vehicles), $AMBA (Hanwha $800M edge AI validation), and $LPTH (Anduril/drone optics NGSRI contract thesis) are not accidents—they're the infrastructure layer for the Trump-era "US-made autonomous kill chain." The market is repricing defense-adjacent software and components as government procurement accelerates, but positioning remains thin. This is a crowded thesis at the institutional level; mass retail has no idea it exists.
IMPORTANT
Federal drone funding announcements are validating small-cap suppliers; $BB's QNX adoption as the only certified OS for safety-critical autonomy is the widest moat.
What's Moving
- $BB (BlackBerry) — QNX RTOS is the only FAA/safety-certified operating system for autonomous devices (275M vehicles, drones, robotics, medical). Switching costs are immovable. Thesis: multi-year hold to $27–29 (intermediate), $56–59 (terminal). (via @nottellingyou73, @crypto_condom, @pdamodaran)
- $AMBA (Ambarella) — Hanwha $800M edge AI/surveillance SoC deal validated. Adding before market digests physical AI + radar-as-alternative-to-LIDAR narrative. (via @OptimusDelta, @citrini positioning)
- $LPTH (Lightpath Technologies) — US-made optical/IR components for drone payloads. Circumstantial evidence of NGSRI Army contract win. ATH momentum, but thesis intact. (via @crypto_condom, @BussinBiotech)
- $IOVA (Iovance Biotherapeutics) — TIL cellular therapy dominance in metastatic solid tumors. FDA-approved product, 20+ year patent moat (vs. 7–12 year pharma), M&A candidate. ASCO data expected imminently. Entry: $3.60–$3.90. (via @crypto_condom large position)
- $ABCL (AbCellera Biologics) — Held in conviction portfolio alongside $BB and $LPTH; smaller position but "make-it" conviction play. (via @crypto_condom)
Crosscurrents
- $BB Tesla adoption claim — @IAMessential316 claimed Tesla using QNX; @crypto_condom verified Tesla uses Linux, not QNX. Rumor risk real, but doesn't break moat; adoption still expanding quietly in aerospace/defense.
- $IOVA timing pressure — Small-cap biotech; options flow visible pre-ASCO. Risk of sell-on-news if expectations already priced in. Patent narrative is strong but clinical data must deliver.
- Retail meme collision — @SmallCapScience noted $SPCE ticker confusion (SpaceX IPO vs. Virgin Galactic). Retail is buying wrong tickers. Defense names could face similar confusion—be precise on tickers.
Tradecraft
BULL
Federal drone spending + autonomous systems mandate creates structural tailwind for QNX, edge AI, and US-made optics for 12–24 months. $BB is the cleanest expression.
BEAR
These are small-cap, low-volume names. $IOVA and $LPTH especially: position sizing required. Conviction traders are already in; retail entry may face slippage.
WATCH
ASCO presentations (next few days) — $IOVA NSCLC data. Congressional funding announcements — $LPTH Congressional allocation tease from management. $BB government equity stake — "Canada Strong Fund" rumor.
Desk Notes
- @crypto_condom — Three conviction "make it" trades: $LPTH, $BB, $ABCL. QNX moat + NGSRI arbitrage + cellular therapy upside. No paid newsletter, free research, holding all three.
- @OptimusDelta — $AMBA core thesis; $EOS.AX (Australian defense, space domain awareness) secondary. 20-year capital markets vet; asymmetric small-cap focus.
- @nottellingyou73 — $BB QNX narrative clarity. Multiyear hold conviction. Only option for safety-certified autonomy.
- @BussinBiotech — $LPTH Anduril optics validation; NGSRI contract front-running. Congressional funding expected soon.